Weight loss

Tirzepatide ODT

Rx · Prescription onlyDissolved under the tongue

Tirzepatide ODT

Weight loss, no needle.

Your plan

$289/mo, $1,734 billed once for 6 months/mo

$1,734 billed once for 6 months · unused months refunded on a medical stop

No membership fee · this is the full price · free shipping · monthly supply

Get started
  • Medication, clinician care and dose adjustments, all in one price.
  • ~30-day supply. Your clinician sets your exact dose, so yours may vary; your refill arrives as you finish the last one.

A licensed clinician on our care team reviews every request and prescribes only when it's clinically appropriate.

FDA status: Compounded medication, not FDA-approved. Its active ingredient, tirzepatide, is also in the FDA-approved drugs Mounjaro and Zepbound; this compounded version is not one of them.

What it's for

Who it's for

People who want tirzepatide and rule out injections.

How it's different

A daily tablet under the tongue. Absorption this way has not been studied the way the injection has, so the effect can be weaker.

How it works

Tirzepatide ODT is a compounded tablet that dissolves under the tongue to deliver the dual hormone-mimicking effect of GLP-1 and GIP. Oral tirzepatide has lower and more variable absorption than injected forms.

How to use it and what arrives

1 bottle · lasts 1 month

Your clinician sets your dose: 3–12 mg · same price at every dose

How
Dissolved under the tongue
How often
Once a day

Good to know

Give it eight weeks at a stable dose before judging it. If it falls short, the injection is the next step, not a higher tablet.

What the research shows

Tirzepatide acts on two gut hormone receptors, GLP-1 and GIP. Its evidence is large randomized trials in adults with obesity, all with the injected form.

  1. Weight

    about 21%

    SURMOUNT-1: 2,539 adults with obesity, or overweight with a weight-related condition, 72 weeks of weekly injections at 5, 10 or 15 mg. At 15 mg the mean loss was 20.9% (intention to treat), against 3.1% on placebo.

    SURMOUNT-1, NEJM 2022
  2. Head to head

    20.2% vs 13.7%

    SURMOUNT-5: 751 adults without diabetes, open label, 72 weeks. Maximum tolerated tirzepatide (10 or 15 mg) lost 20.2% on average; maximum tolerated semaglutide (1.7 or 2.4 mg) lost 13.7%.

    SURMOUNT-5, NEJM 2025
  3. Large losses

    57% lost 20% or more

    SURMOUNT-1 at 15 mg: 57% of people reached a loss of at least 20% of body weight, against 3% on placebo. The average hides a wide spread between people.

    SURMOUNT-1, NEJM 2022

Trial results are for the injected tirzepatide at the doses studied. They are averages, not predictions for one person. No trial has tested the sublingual (dissolve-under-the-tongue) form or the compounded blends.

What this does not say

  • SURMOUNT-5 was open label and run by the manufacturer of tirzepatide, so the head-to-head result needs an independent check.
  • The trials ran 52 to 72 weeks. Effects after stopping were not part of them, though SURMOUNT-4 shows regain after withdrawal.
  • Between 4.3% and 7.1% of people on tirzepatide stopped for adverse events in SURMOUNT-1, against 2.6% on placebo.

Sources

  1. Oral semaglutide 2.4 mg once daily with permeation enhancers: a phase 2b trial for weight loss. NEJM, 2019 (Buckley ST et al.)
  2. Semaglutide injection (Ozempic) mechanism and GLP-1 receptor agonism. Lancet, 2021 (Wilding JPH et al.)
Read the full research

Safety

FDA status: Compounded medication, not FDA-approved. Its active ingredient, tirzepatide, is also in the FDA-approved drugs Mounjaro and Zepbound; this compounded version is not one of them.

Side effects and precautions

  • Oral semaglutide and tirzepatide are experimental formulations with limited human data.
  • Common effects include nausea, diarrhea, constipation, and reduced appetite, often in the first weeks as absorption settles.
  • Absorption is variable; blood levels may be unpredictable.
  • Not for pregnancy or breastfeeding, or with a history of pancreatitis.

Get care right away

  • Stop and seek care for severe abdominal pain, signs of pancreatitis, allergic reactions, or vision changes if diabetic.

When it isn't prescribed

  • Do not use if you or a family member has had medullary thyroid carcinoma or MEN 2.

Tell your clinician about all medications, diabetes drugs, and any history of kidney or pancreatic disease.

Questions

How does oral tirzepatide compare to the shot?

Injected tirzepatide has proven efficacy and predictable blood levels. Oral tirzepatide is newer and less studied. Your clinician may prescribe a higher initial dose to account for variable absorption.

Why oral instead of injection?

Oral forms avoid needles. Be aware: absorption is unpredictable and lower than injections, so effects are less reliable. Your clinician will adjust your dose frequently as you respond.

What if absorption is poor?

If you see minimal effect after 4–6 weeks at a good dose, your clinician may increase the dose, try a different formulation, or recommend switching to injected GLP-1 for better reliability.

How often will I need adjustments?

Frequently at first, every 1–2 weeks in the first month, to find your effective dose. Once stable, check-ins may space out to monthly or every 2 months.

Can I switch between oral and injection?

Yes. If oral doesn't work well or you need more predictable results, your clinician can switch you to injected semaglutide or tirzepatide.

Still have a question? Message our team

Ready to start with Tirzepatide ODT?

$289/mo · $1,734 billed once for 6 months

Get started
  • Free shipping on every order
  • No membership fee
  • Same price at every dose
  • HSA and FSA accepted

More options in this area